Dan Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dan Huang has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Arwa Qaqish
Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan
1 shared publication Bin-He Chang
CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
1 shared publicationBing-Yi Chen
CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
1 shared publicationCheng-Long Hu
CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
1 shared publicationChong Zhao
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publicationChu-Han Deng
CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
1 shared publication
Latest Publications
- 4 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (1) , 84-95
AKT inhibitor capivasertib reverses EVI1‐driven resistance to venetoclax in acute myeloid leukaemia
Summary: Acute myeloid leukaemia (AML) with MDS1 and EVI1 complex locus ( MECOM ) rearrangement is recognized by the World Health Organization as a distinct entity characterized by poor prognosis and aggressive disease progression. This rearrangement evokes aberrant ecotropic viral integration site 1 ( EVI1 ) overexpression, which enhances leukaemic stem cell self‐renewal and drives chemoresistance. However, the mechanisms by which EVI1 contributes to venetoclax resistance remain unclear. In this study, patients with AML were stratified into the EVI1 ‐high and EVI1 ‐low groups based on transcript levels. The EVI1 ‐high subgroup exhibited significantly inferior clinical outcomes and reduced complete remission rates following chemotherapy or venetoclax‐based regimens. Meanwhile, we demonstrated that elevated EVI1 expression confers resistance to venetoclax by stabilizing myeloid cell leukaemia 1 (MCL‐1) through activation of the phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT) signalling pathway in vitro. Mechanistically, elevated EVI1 levels were associated with increased phosphorylation of MCL‐1 at threonine 163 (T163pMCL‐1), thereby stabilizing MCL‐1 by attenuating its ubiquitin–proteasome‐mediated degradation. Importantly, cotreatment with venetoclax and the clinically available AKT inhibitor capivasertib effectively restored sensitivity in both cell lines and patient‐derived primary AML samples with high EVI1 expression. Overall, our findings reveal a novel molecular mechanism underlying EVI1‐mediated venetoclax resistance through PI3K/AKT‐driven MCL‐1 stabilization and suggest a combination strategy involving AKT inhibition as a promising approach for overcoming therapeutic resistance in this high‐risk AML subset.
- 4 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (1) , 84-95
AKT inhibitor capivasertib reverses EVI1‐driven resistance to venetoclax in acute myeloid leukaemia
Summary: Acute myeloid leukaemia (AML) with MDS1 and EVI1 complex locus ( MECOM ) rearrangement is recognized by the World Health Organization as a distinct entity characterized by poor prognosis and aggressive disease progression. This rearrangement evokes aberrant ecotropic viral integration site 1 ( EVI1 ) overexpression, which enhances leukaemic stem cell self‐renewal and drives chemoresistance. However, the mechanisms by which EVI1 contributes to venetoclax resistance remain unclear. In this study, patients with AML were stratified into the EVI1 ‐high and EVI1 ‐low groups based on transcript levels. The EVI1 ‐high subgroup exhibited significantly inferior clinical outcomes and reduced complete remission rates following chemotherapy or venetoclax‐based regimens. Meanwhile, we demonstrated that elevated EVI1 expression confers resistance to venetoclax by stabilizing myeloid cell leukaemia 1 (MCL‐1) through activation of the phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT) signalling pathway in vitro. Mechanistically, elevated EVI1 levels were associated with increased phosphorylation of MCL‐1 at threonine 163 (T163pMCL‐1), thereby stabilizing MCL‐1 by attenuating its ubiquitin–proteasome‐mediated degradation. Importantly, cotreatment with venetoclax and the clinically available AKT inhibitor capivasertib effectively restored sensitivity in both cell lines and patient‐derived primary AML samples with high EVI1 expression. Overall, our findings reveal a novel molecular mechanism underlying EVI1‐mediated venetoclax resistance through PI3K/AKT‐driven MCL‐1 stabilization and suggest a combination strategy involving AKT inhibition as a promising approach for overcoming therapeutic resistance in this high‐risk AML subset.
- Open Access
- 7 September 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (10) , 903-917
The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment
The bone marrow microenvironment (BMM) can regulate leukemia stem cells (LSCs) via secreted factors. Increasing evidence suggests that dissecting the mechanisms by which the BMM maintains LSCs may lead to the development of effective therapies for the eradication of leukemia. Inhibitor of DNA binding 1 (ID1), a key transcriptional regulator in LSCs, previously identified by us, controls cytokine production in the BMM, but the role of ID1 in acute myeloid leukemia (AML) BMM remains obscure. Here, we report that ID1 is highly expressed in the BMM of patients with AML, especially in BM mesenchymal stem cells, and that the high expression of ID1 in the AML BMM is induced by BMP6, secreted from AML cells. Knocking out ID1 in mesenchymal cells significantly suppresses the proliferation of cocultured AML cells. Loss of Id1 in the BMM results in impaired AML progression in AML mouse models. Mechanistically, we found that Id1 deficiency significantly reduces SP1 protein levels in mesenchymal cells cocultured with AML cells. Using ID1-interactome analysis, we found that ID1 interacts with RNF4, an E3 ubiquitin ligase, and causes a decrease in SP1 ubiquitination. Disrupting the ID1-RNF4 interaction via truncation in mesenchymal cells significantly reduces SP1 protein levels and delays AML cell proliferation. We identify that the target of Sp1, Angptl7, is the primary differentially expression protein factor in Id1-deficient BM supernatant fluid to regulate AML progression in mice. Our study highlights the critical role of ID1 in the AML BMM and aids the development of therapeutic strategies for AML.
- 7 September 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (10) , 903-917
Open AccessThe non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment
The bone marrow microenvironment (BMM) can regulate leukemia stem cells (LSCs) via secreted factors. Increasing evidence suggests that dissecting the mechanisms by which the BMM maintains LSCs may lead to the development of effective therapies for the eradication of leukemia. Inhibitor of DNA binding 1 (ID1), a key transcriptional regulator in LSCs, previously identified by us, controls cytokine production in the BMM, but the role of ID1 in acute myeloid leukemia (AML) BMM remains obscure. Here, we report that ID1 is highly expressed in the BMM of patients with AML, especially in BM mesenchymal stem cells, and that the high expression of ID1 in the AML BMM is induced by BMP6, secreted from AML cells. Knocking out ID1 in mesenchymal cells significantly suppresses the proliferation of cocultured AML cells. Loss of Id1 in the BMM results in impaired AML progression in AML mouse models. Mechanistically, we found that Id1 deficiency significantly reduces SP1 protein levels in mesenchymal cells cocultured with AML cells. Using ID1-interactome analysis, we found that ID1 interacts with RNF4, an E3 ubiquitin ligase, and causes a decrease in SP1 ubiquitination. Disrupting the ID1-RNF4 interaction via truncation in mesenchymal cells significantly reduces SP1 protein levels and delays AML cell proliferation. We identify that the target of Sp1, Angptl7, is the primary differentially expression protein factor in Id1-deficient BM supernatant fluid to regulate AML progression in mice. Our study highlights the critical role of ID1 in the AML BMM and aids the development of therapeutic strategies for AML.
- 10 October 2020
- Published by Wiley in Immunological Reviews
- Vol. 298 (1) , 254-263
Fast‐acting γδ T‐cell subpopulation and protective immunity against infections
Unique Vγ2Vδ2 (Vγ9Vδ2) T cells existing only in human and non‐human primates, account for the majority of circulating γδ T cells in human adults. Vγ2Vδ2 T cells are the sole γδ T‐cell subpopulation capable of recognizing the microbial (E)‐4‐hydroxy‐3‐methyl‐but‐2‐enyl pyrophosphate (HMBPP) produced by selected pathogens during infections. Recent seminal studies in non‐human primate models have demonstrated that the unique HMBPP‐specific Vγ2Vδ2 T cells are fast‐acting, multi‐functional, and protective during infections. This article reviews the recent seminal observations of Vγ2Vδ2 T cells in protective mechanisms against tuberculosis and other infections.
- 10 October 2020
- Published by Wiley in Immunological Reviews
- Vol. 298 (1) , 254-263
Fast‐acting γδ T‐cell subpopulation and protective immunity against infections
Unique Vγ2Vδ2 (Vγ9Vδ2) T cells existing only in human and non‐human primates, account for the majority of circulating γδ T cells in human adults. Vγ2Vδ2 T cells are the sole γδ T‐cell subpopulation capable of recognizing the microbial (E)‐4‐hydroxy‐3‐methyl‐but‐2‐enyl pyrophosphate (HMBPP) produced by selected pathogens during infections. Recent seminal studies in non‐human primate models have demonstrated that the unique HMBPP‐specific Vγ2Vδ2 T cells are fast‐acting, multi‐functional, and protective during infections. This article reviews the recent seminal observations of Vγ2Vδ2 T cells in protective mechanisms against tuberculosis and other infections.